The Alzheimer's disease cooperative study in 2004

Alzheimer Disease and Associated Disorders

Volumn 18, Issue 4, 2004, Pages 183-185

  Thal, Leon J ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; CHOLINESTERASE INHIBITOR; CONJUGATED ESTROGEN; MUSCARINIC AGENT; SELEGILINE; TACRINE;

AGING; ALZHEIMER DISEASE; CLINICAL TRIAL; COGNITION; HUMAN; LEARNING; MEMORY; NEUROPSYCHOLOGY; PRIORITY JOURNAL; SHORT SURVEY;

ALZHEIMER DISEASE; CLINICAL TRIALS; COGNITION DISORDERS; DISEASE PROGRESSION; HUMANS; MULTICENTER STUDIES; NEUROLOGY;

EID: 11344287679     PISSN: 08930341     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Short Survey

References (13)

1. Blessed G, Tomlinson BE, Roth M. The association between quantitative measures of dementia and of senile change in the cerebral grey matter of elderly subjects. Br J Psychiatry. 1968;114:797-811.
2. Katzman R. The prevalence of malignancy of Alzheimer's disease. Arch Neural. 1976;33:217-218.
3. Davies P, Maloney AJF. Selective loss of central cholinergic neurons in Alzheimer's disease. Lancet. 1976;2:1403.
4. Davis KL, Mohs RC. Enhancement of memory processes in Alzheimer's disease with multiple-dose intravenous physostigmine. Am J Psychiatry. 1982;139:1421-1424.
5. Thal LJ, Fuld PA, Masur DM, et al. Oral physostigmine and lecithin improve memory in Alzheimer's disease. Ann Neurol. 1983;13:491-496.
6. Summers WK, Majorski LV, Marsh GM, et al. Oral tetrahydroaminoacridine in long-term treatment of senile dementia, Alzheimer type. N Engl J Med. 1986;315:1241-1245.
7. Leber P. Guidelines for the Clinical Evaluation of Anti-Dementia Drugs, 1st draft. U.S. Rockville, MD: Food and Drug Administration, 1990.
8. Davis KL, Thal LJ, Gamzu E, et al. Tacrine in patients with Alzheimer's disease: a double-blind, placebo-controlled multicenter study of tacrine for AD. N Engl J Med. 1992;327:1253-1259.
9. Knapp MJ, Knopman DS, Solomon PR, et al. A 30-week randomized controlled trial of high-dose tacrine in patients with Alzheimer's disease. JAMA. 1994;271:985-991.
10. Sano M, Ernesto C, Thomas RG, et al. A controlled trial of selegiline, α-tocopherol, or both as treatment for Alzheimer's disease. N Engl J Med. 1997;336:1216-1222.
11. Mulnard RA, Cotman CW, Kawas C, et al. Estrogen replacement therapy for treatment of mild to moderate Alzheimer's disease: a one-year randomized clinical trial. JAMA. 2000;283:1007-1015.
12. Shumaker SA, Legault C, Rapp SR, et al. Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women. The Women's Health Initiative memory study: a randomized controlled trial. JAMA. 2003;289:2651-2662.
13. Petersen RC, Smith GE, Waring SC, et al. Mild cognitive impairment: clinical characterization and outcome. Arch Neurol. 1999;56:303-308.